Open to all scientists researching new therapeutics in Cambridge and the local area.

The purpose of the CamNTF is to promote interactions between scientists from academia & industry in order to improve opportunities for biotechnology research and development. Meeting attendance is free but all attendees must register in advance

Host: AstraZeneca

Date: Wednesday 2nd September 2020

Location: This event will take place online. Please register on Eventbrite and details will follow closer to the time.

Programme

18:00 – Welcome

18:05 – Dr Oliver Rausch, CSO at Storm Therapeutics

RNA Epigenetics - targeting the RNA-m6A writer METTL3 for the treatment of cancer

18:35 – Dr Joanna Holbrook, Senior Vice President of Research, Cambridge Epigenetix

Tracking disease through the epigenome

18:50 – Dr Mark McAlister, Associate Director, Biophysics, AstraZeneca

The discovery and unique mechanism of BiBET (AZD5153) – a potent clinical-stage

BET inhibitor

19:10 – Meeting close